左西孟旦联合沙库巴曲缬沙坦钠在急性前壁心肌梗死PCI术后早期应用的临床研究  

Clinical Study on the Early Application of Levosimendan Combined with Sacubitril Valsartan Sodium in Acute Anterior Myocardial Infarction after PCI

作　　者：刘兴龙 姚常[1] 罗勤[1] 周国忠[1] 黄文军[1] LIU Xinglong;YAO Chang;LUO Qin;ZHOU Guozhong;HUANG Wenjun(Department of Cardiovascular Medicine,Pingxiang People's Hospital,Pingxiang 337000,China;不详)

机构地区：[1]萍乡市人民医院心血管内科,江西萍乡337000

出　　处：《中国医学创新》2024年第16期16-20,共5页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(SKJP220218236)。

摘　　要：目的:探讨左西孟旦联合沙库巴曲缬沙坦钠在急性前壁心肌梗死经皮冠状动脉介入治疗(PCI)术后的应用效果。方法:选取2021年9月—2023年9月萍乡市人民医院心内科收治的120例急性前壁心肌梗死PCI术后早期心力衰竭患者,采用随机数字表法分为观察组(n=60)和对照组(n=60)。对照组采用沙库巴曲缬沙坦钠治疗,观察组采用左西孟旦联合沙库巴曲缬沙坦钠治疗,两组均治疗7 d。比较两组临床疗效、心功能及心室重塑指标、血清学指标及不良反应。结果:观察组总有效率高于对照组(P<0.05)。治疗后,两组左室射血分数(LVEF)均较治疗前上升,且观察组更高,两组左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、室间隔厚度(IVST)、左室后壁厚度(LVPWT)均较治疗前下降,且观察组均更低(P<0.05)。治疗后,两组N末端脑钠肽前体(NT-proBNP)、C反应蛋白(CRP)均较治疗前下降,且观察组均更低(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:左西孟旦联合沙库巴曲缬沙坦钠应用于急性前壁心肌梗死PCI术后早期心力衰竭患者效果确切,可改善心功能及心室重塑,抑制炎症反应,安全可靠。Objective:To explore the application effect of early application of Levosimendan combined with Sacubitril Valsartan Sodium in acute anterior myocardial infarction after percutaneous coronary intervention(PCI).Method:A total of 120 patients with early heart failure after PCI for acute anterior myocardial infarction admitted to Department of Cardiovascular Medicine,Pingxiang People's Hospital from September 2021 to September 2023 were selected and divided into observation group(n=60)and control group(n=60)by random number table method.The control group was treated with Sacubitril Valsartan Sodium,and the observation group was treated with Levosimendan combined with Sacubitril Valsartan Sodium,both groups were treated for 7 days.The clinical efficacy,cardiac function and ventricular remodeling indexes,serological indexes and adverse reactions were compared between the two groups.Result:The total effective rate of observation group was higher than that of control group(P<0.05).After treatment,left ventricular ejection fraction(LVEF)in both groups increased compared with that before treatment,and that in the observation group was higher,left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),interventricular septal thickness(IVST)and left ventricular posterior wall thickness(LVPWT)in both groups decreased compared with those before treatment,and those in the observation group were lower(P<0.05).After treatment,the N-terminal probrain natriuretic peptide(NT-proBNP)and C reactive protein(CRP)in both groups were decreased compared with those before treatment,and those in the observation group were lower(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Levosimendan combined with Sacubitril Valsartan Sodium is effective in patients with early heart failure after PCI for acute anterior myocardial infarction,can improve cardiac function and ventricular remodeling,inhibit inflammatory response,and is safe and reliab

关 键 词：急性前壁心肌梗死 经皮冠状动脉介入治疗 心力衰竭 左西孟旦 沙库巴曲缬沙坦钠 

分 类 号：R542.22[医药卫生—心血管疾病]